

IN THE LINE DESTATES PATENT AND TRADEMARK OFFICE

In re Application of:	")	***
LIANG ET AL.)	Group Art No: Unassigned
Serial No: 10/070560)	Examiner: Unassigned
Filed: March 8, 2002)	
For: METHOD OF PRODUCING AND PURIFY ENDOSTATIN PROTEIN	ING)	

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, DC 20231

Sir:

The citation of information on the attached Form PTO/SB/08A, "List of Art Cited by Applicant" is made pursuant to 37 C.F.R. §§ 1.97 and 1.98. A copy of all listed items is enclosed. The citation of this information does not constitute an admission that any of the materials are available as a reference or of priority, or a waiver of any right applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

By: Theodore M. Green

Reg. No. 41,801

KILPATRICK STOCKTON LLP

Suite 2800 1100 Peachtree Road Atlanta, Georgia 30309

(404) 815-6500

Our Docket: 05213-0551US (43170-258385)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC, 20231, on June 6, 2002.

sy: Mothy W Du

Theodore M. Green - Reg. No. 41,801

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: Usare required to respond to a collection of information unless

PARTMENT OF COMMERCE ins a valid OMB control number

Under the Paperwork Reduction Act of 19

Substitute for Form 1449/A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

1 of 3

Complete if Known						
Application No.	10/070560					
Filing Date	11/30/2001					
First Named Inventor	Liang et al.					
Group Art Unit	Not Yet Assigned					
Examiner Name	Unassigned					
Attorney Docket Number	05213-0551US(43170-258385)					

U.S. PATENT DOCUMENTS							
Examiner	Cite	U.S. Patent Docume	nţ		Date of Publication	Pages, Columns, Lines, Where	
Initials	No.1		Kind Code ^s if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY		
	1	5,854,205		O'Reilly et al.	12/29/1998		

Examiner	Date	
Signature	Considered	

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995 no control number as a recognised to respond to a collection of information unless the ontains a valid OMB control number

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete i							
Application No.	10/070560						
Filing Date	03/08/2002						
First Named Inventor	Liang et al.						
Group Art Unit	Unassigned						
Examiner Name	Unassigned						
Attorney Docket Number	05213-0551US(43170-258385)						

				FO	REIGN PATENT DOCUMI	ENTS		
Examiner Cite No.1 Office		Office'	Foreign Patent De	ocument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	2	wo	96/08274	A2	Prizm Pharmaceuticals, Inc.	03/21/1996		
	3	wo	99/26480	A1	Genetix Pharmaceuticals, Inc. and	06/03/1999		Γ

	,	
Examiner	Date	
Signature	Considered	

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

has are equire to respond to a collection of information Under the Paperwork Reduction Act of 19 s it contains a valid OMB control number

Substitute for Form 1449/A/PTO

STATEMENT BY APPL

INFORMATION DISCLOSUR (use as many sheets as necessary)

if Known Application No. 10/070560 Filing Date 03/08/2002 First Named Inventor Liang et al. Group Art Unit Unassigned **Examiner Name** Unassigned

Sheet		3	of	3			Attorney Docket Numb	oer 05213-0551	US(43170-	258385)	
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS											
Examiner Initials	Cite No. ¹		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published								
	4	Author: B(ЕНМ	ET AL.			of the KEX1 Gene in <i>Pichia</i> I Human Endostatin	pastoris Allows Express	ion of Full-	Length	
		Yeast					Vol/lss: 15	Pages: 563-572	Date:	1999	
	5	Author: B(ЕНМ	ET AL.	Title:	Zinc-Bindi	ng of Endostatin is Essential	for Its Antiangiogenic A	ctivity		
		Publ: Biochemica	l and F	Biophysical Resea	rch Commu	nications	Vol/Iss: 252	Pages: 190-194	Date:	1998	
	6	Author: DI	IANA	BAL ET AL.	Title:	Endostatin:	Yeast Production, Mutants,	and Antitumor Effect in l	Renal Cell	Carcinoma	<u> </u>
		Publ: Cancer Rese	earch				Vol/iss: 59	Pages: 189-197	Date: 0	01/01/199	
	7	Author: JO	Author: JOHN ET AL. Title: Novel Glycosylated Forms of Human Plasma Endostatin and Circulating Endostatin-Related Fragments of Collagen XV								
		Biochemistr	¥				Vol/lss: 38 (32)	Pages: 10217-10224	Date: 0	8/10/199	
	8	Author: SHEPARD ET AL. Title: Purification of Recombinant Human Endostatin and Angiostatin from Pichia Pastoris Fermentation Broth: Expanded Bed Adsoption Chromatography Method Publ: Development and Scale III									
		Abstracts of	Paper	s American Chen	nical Society		Vol/lss: 219 (1-2)	Pages: BIOT 212	Date: 0	3/26/200	
	9	Author: ST	`ANDI	KER et al.	Title:	Isolation a	nd characterization of the circ	ulating form of human e	ndostatin		
		FEBS Lette	rs				Vol/Iss: 420	Pages: 129-133	Date:	1997	

Examiner	Date	
Signature	Considered	